Kent Christopherson
Global Medical Affairs Head Orchard Therapeutics
Kent is an accomplished medical affairs leader with >25 years of experience in cell & gene therapy and a proven track record of product launches within rare genetic diseases. He is currently Head of Global Medical Affairs at Orchard Therapeutics. In this role, he leads global medical strategy across both commercial gene therapies and clinical development stage gene therapies, while also supporting early-stage translational research programs. Kent?s personal mission is to accelerate innovation in cell & gene therapy and ensure that breakthrough science reaches the patients who need it the most.
Seminars
Monday 23rd March 2026
Workshop B: Designing Your First Expanded Access Program from Strategy to Launch
12:00 pm
- Translating organizational goals into a practical EAP strategy tailored to your patient population
- Balancing ethical considerations with trial integrity to determine optimal timing and access
- Planning program scope, cross-functional coordination, and vendor engagement for smooth execution
Thursday 26th March 2026
Gene Therapies: Global Pathways to Bridge Innovation & Access
3:45 pm
- Enabling early patient access to investigational gene therapies through global pre-approval pathways and compassionate use programs
- Supporting patient access to gene therapy treatment with managed and conditional post-approval models
- Strengthening safety, effectiveness, and global alignment by leveraging multi-stakeholder data and collaboration
